PLOS One

This article tracks the progression of anti-spike SARS-CoV-2 antibody titers at two-time points within a cohort of 201 adults who received Pfizer-BioNTech (BNT162b2), AstraZeneca, or Sputnik V vaccines in North Lebanon.

Journal Article